Oxford GlycoSciences and Incyte Launch Proteomics Drug Discovery Program | GenomeWeb

BOSTON--Incyte Pharmaceuticals of Palo Alto, Calif., and Oxford GlycoSciences of Oxford, UK, jointly launched the LifeProgram protein expression product last month at the IBC Drug Discovery Technology Conference here. LifeProgram facilitates the identification and validation of new drug targets, therapeutic proteins, and human disease markers. This new program provides an extensive proteomics database, software to analyze and visualize proteomics data, and access to optional customer-directed services at Oxford to develop custom protein expression data.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.